loader image
Sunday, November 30, 2025
69.7 F
McAllen
- Advertisement -

From Mild Cognitive Impairment to Alzheimer’s 

Translate to Spanish or other 102 languages!

How can we predict who will progress to Alzheimer’s from mild cognitive impairment. Image for illustration purposes
How can we predict who will progress to Alzheimer’s from mild cognitive impairment. Image for illustration purposes

Medical News Today

- Advertisement -
  • Dementia affects more than 55 million people worldwide, costing around $1.3 trillion per year.
  • The most common form of dementia, Alzheimer’s disease, affects up to 70% of these people.
  • New treatments are most effective if started early in the progression of the disease, but diagnosis is difficult at this stage as early symptoms are often dismissed as normal changes due to aging.
  • Now, a new study has developed a deep learning framework that can identify the risk of progressing from mild cognitive impairment to Alzheimer’s.

In 2019, according to the Global Burden of Diseases, Injuries, and Risk Factors StudyTrusted Source, an estimated 57.4 million people worldwide had dementia.

Follow the link below to read the entire article on Medical News Today: 

https://www.medicalnewstoday.com/articles/from-mild-cognitive-impairment-to-alzheimers-predicting-risk?utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2023-08-10&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Behavioral Hosting Webinar on Seasonal Depression, Dec. 4

Mega Doctor News It’s common for individuals to experience an emotional downturn during the winter...

AMA Adopts New Public Health Policies to Improve Health of the Nation

The American Medical Association (AMA) gathered physician and medical student leaders from all corners of medicine at its Interim Meeting of the House of Delegates to shape guiding policies on emerging health care topics.

Study Finds Best Strategy for Reducing Belly Fat

Over the last few years, research has shown that having excessive visceral fat — the fat surrounding the abdominal area that protects internal organs — can be detrimental to a person’s health.

FDA Approves Gene Therapy for Treatment of Spinal Muscular Atrophy

The U.S. Food and Drug Administration approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in the survival motor neuron 1 (SMN1) gene. Itvisma is an adeno-associated virus (AAV) vector-based gene therapy.
- Advertisement -
×